You are here
Survey: Gastroenterologists Applaud Cell Adhesion Molecule Inhibitor Vedolizumab (Entyvio)
Decision Resources Group, a health care research firm located in Burlington, Mass., has found that at 1 month post-launch, most surveyed gastroenterologists were aware of and familiar with vedolizumab (Entyvio, Takeda) as a new therapy for the treatment of moderate-to-severe ulcerative colitis (UC) and/or Crohn’s disease (CD).
According to surveyed gastroenterologists, the most commonly cited advantage of vedolizumab compared with other currently available biologic treatments was its different mechanism of action. At 1 month post-launch, less than 20% of surveyed gastroenterologists reported prescribing vedolizumab to their UC and/or CD patients.
Less than half of surveyed gastroenterologists were satisfied with the currently available products for moderate-to-severe UC and/or CD, and most agreed that there is a need for alternative therapies.
Although the risk of progressive multifocal leukoencephalopathy associated with vedolizumab was a concern for most surveyed gastroenterologists, most of the respondents anticipated prescribing the agent to their patients with UC and/or CD within 1 year.
According to surveyed gastroenterologists, tumor necrosis factor (TNF)-refractory patients with UC and/or CD are the ideal candidates for treatment with vedolizumab. Infliximab (Remicade, Janssen Biotech) and adalimumab (Humira, AbbVie) are likely to remain the first-line biologic agents for patients with moderate-to-severe UC and/or CD.
“High opportunity exists for emerging therapies in the inflammatory bowel disease market,” said analyst Adi Reske, PhD. “Improved efficacy in the acute and maintenance setting, long-term safety, and more convenient dosing formulations are the highly desired attributes for products in development for UC and CD.”
Source: BioTrends Research Group; September 29, 2014.